Receptor Expression | NG2 expression |
---|
Sample | Stage | HER2 | ER | PR | tumor cells | pericytes | macrophages | adipocytes |
---|
1 | 2 | 6+ | 4+ | - | - | 3+ | ND | 4+ |
2 | 3 | - | 4+ | - | 2+ | 2+ | ND | 2+ |
3 | 3 | - | 4+ | 3+ | - | 2+ | ND | 2+ |
4 | 2 | - | - | 3+ | - | 1+ | ND | ND |
5 | 2 | - | 4+ | - | - | 2+ | 1+ | ND |
6 | 2 | ND | 4+ | 3+ | 2+ | 1+ | ND | 2+ |
7 | 2 | 2+ | 4+ | 3+ | - | 2+ | ND | ND |
8 | 1 | ND | 4+ | 3+ | - | 1+ | 1+ | 1+ |
9 | 1 | 2+ | 4+ | 3+ | - | 2+ | 1+ | ND |
10 | 1 | 3+ | 4+ | 3+ | 2+ | 2+ | ND | 2+ |
11 | 2 | - | 4+ | ND | - | 2+ | ND | 2+ |
- Intensity of receptor or NG2 expression was judged by immunofluorescence on a scale of 1 to 6, with 6 being the most intense. Pathological tumor stages are graded on a scale of 1 to 4, with 4 being the most malignant. NG2 expression in pericytes was judged by triple staining for NG2, α-smooth muscle actin, and CD31. NG2 expression in macrophages was judged by double staining for NG2 and CD11b. Adipocytes were recognized on the basis of size and morphology (some samples did not have recognizable adipocytes, hence the ND notation). Images in Figure 2 were taken from samples 1, 3, and 8. ER, estrogen receptor; HER2, HER2 EGF receptor; ND, not determined; PR, progesterone receptor.